Principal Financial Group Inc Editas Medicine, Inc. Transaction History

Principal Financial Group Inc

$162 Billion
Q1 2024

A detailed history of Principal Financial Group Inc transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 20,029 shares of EDIT stock, worth $100,145. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,029

Previous 21,804 8.14%

Holding current value

$100,145

Previous $220,000 32.73%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	SELL	$7.03 - $11.07 $12,478 - $19,649	-1,775 Reduced 8.14%	20,029 $148,000
Q4 2023 Feb 07, 2024	SELL	$6.25 - $11.11 $14,956 - $26,586	-2,393 Reduced 9.89%	21,804 $220,000
Q3 2023 Nov 02, 2023	BUY	$6.92 - $9.31 $35,997 - $48,430	5,202 Added 27.39%	24,197 $188,000
Q2 2023 Aug 07, 2023	BUY	$6.36 - $11.47 $4,750 - $8,568	747 Added 4.09%	18,995 $156,000
Q1 2023 May 09, 2023	BUY	$7.03 - $11.53 $19,072 - $31,280	2,713 Added 17.46%	18,248 $132,000

Q4 2022 Feb 09, 2023	BUY	$8.32 - $13.21 $3,952 - $6,274	475 Added 3.15%	15,535 $137,000
Q3 2022 Nov 09, 2022	BUY	$12.16 - $19.42 $45,745 - $73,058	3,762 Added 33.3%	15,060 $184,000
Q2 2022 Aug 10, 2022	SELL	$9.99 - $21.35 $12,217 - $26,111	-1,223 Reduced 9.77%	11,298 $134,000
Q1 2022 May 09, 2022	SELL	$14.08 - $27.63 $102,502 - $201,146	-7,280 Reduced 36.77%	12,521 $238,000
Q4 2021 Feb 09, 2022	SELL	$26.55 - $40.57 $218,957 - $334,580	-8,247 Reduced 29.4%	19,801 $526,000
Q3 2021 Nov 09, 2021	BUY	$39.27 - $72.94 $61,339 - $113,932	1,562 Added 5.9%	28,048 $1.15 Million
Q2 2021 Aug 10, 2021	SELL	$31.29 - $56.64 $49,751 - $90,057	-1,590 Reduced 5.66%	26,486 $1.5 Million
Q1 2021 May 10, 2021	SELL	$39.71 - $90.58 $27,439 - $62,590	-691 Reduced 2.4%	28,076 $1.18 Million
Q4 2020 Feb 08, 2021	BUY	$27.07 - $84.35 $229,066 - $713,769	8,462 Added 41.67%	28,767 $2.02 Million
Q3 2020 Nov 06, 2020	BUY	$28.06 - $37.16 $5,415 - $7,171	193 Added 0.96%	20,305 $569,000
Q2 2020 Aug 05, 2020	BUY	$18.5 - $34.34 $372,072 - $690,646	20,112 New	20,112 $595,000
Q1 2020 May 12, 2020	SELL	$14.88 - $32.78 $107,552 - $236,933	-7,228 Closed	0 $0
Q4 2019 Feb 05, 2020	BUY	$19.49 - $32.63 $140,873 - $235,849	7,228 New	7,228 $214,000
Q4 2018 Feb 14, 2019	SELL	$18.19 - $31.79 $290,494 - $507,686	-15,970 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$27.65 - $38.39 $63,014 - $87,490	2,279 Added 16.65%	15,970 $508,000
Q2 2018 Aug 13, 2018	BUY	$31.4 - $41.01 $194,962 - $254,631	6,209 Added 82.99%	13,691 $0
Q1 2018 May 14, 2018	BUY	$29.84 - $44.08 $20,082 - $29,665	673 Added 9.88%	7,482 $248,000
Q4 2017 Feb 13, 2018	BUY	$21.89 - $31.34 $149,049 - $213,394	6,809	6,809 $209,000

Others Institutions Holding EDIT

# of Institutions

250

Shares Held

69.6M

Call Options Held

564K

Put Options Held

428K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $344M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account

Principal Financial Group Inc Editas Medicine, Inc. Transaction History